364 related articles for article (PubMed ID: 33758105)
1. mTOR inhibition improves mitochondria function/biogenesis and delays cardiovascular aging in kidney transplant recipients with chronic graft dysfunction.
Infante B; Bellanti F; Correale M; Pontrelli P; Franzin R; Leo S; Calvaruso M; Mercuri S; Netti GS; Ranieri E; Brunetti ND; Grandaliano G; Gesualdo L; Serviddio G; Castellano G; Stallone G
Aging (Albany NY); 2021 Mar; 13(6):8026-8039. PubMed ID: 33758105
[TBL] [Abstract][Full Text] [Related]
2. An mTOR-inhibitor-based protocol and calcineurin inhibitor (CNI)-free treatment in kidney transplant recipients from donors after cardiac death: good renal function, but high incidence of conversion to CNI.
Sánchez-Escuredo A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofán F; Torregrosa JV; Peri L; Ruiz Á; Campistol JM; Oppenheimer F
Transpl Int; 2016 Mar; 29(3):362-8. PubMed ID: 26678359
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.
Paoletti E; Citterio F; Corsini A; Potena L; Rigotti P; Sandrini S; Bussalino E; Stallone G;
J Nephrol; 2020 Feb; 33(1):69-82. PubMed ID: 31028549
[TBL] [Abstract][Full Text] [Related]
4. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
[TBL] [Abstract][Full Text] [Related]
5. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
[TBL] [Abstract][Full Text] [Related]
6. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
7. mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?
Holdaas H; Potena L; Saliba F
Transplant Rev (Orlando); 2015 Apr; 29(2):93-102. PubMed ID: 25227328
[TBL] [Abstract][Full Text] [Related]
8. Long-term cardiovascular outcome of renal transplant recipients after early conversion to everolimus compared to calcineurin inhibition: results from the randomized controlled MECANO trial.
van Dijk M; van Roon AM; Said MY; Bemelman FJ; Homan van der Heide JJ; de Fijter HW; de Vries APJ; Bakker SJL; Sanders JSF
Transpl Int; 2018 Dec; 31(12):1380-1390. PubMed ID: 30106185
[TBL] [Abstract][Full Text] [Related]
9. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
11. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive minimization with mTOR inhibitors and belatacept.
Diekmann F
Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
[TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Johnson SC; Martinez F; Bitto A; Gonzalez B; Tazaerslan C; Cohen C; Delaval L; Timsit J; Knebelmann B; Terzi F; Mahal T; Zhu Y; Morgan PG; Sedensky MM; Kaeberlein M; Legendre C; Suh Y; Canaud G
Kidney Int; 2019 Feb; 95(2):455-466. PubMed ID: 30471880
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitors in pediatric liver transplant recipients.
Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
[TBL] [Abstract][Full Text] [Related]
16. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.
Nashan B
Clin Transplant; 2013; 27 Suppl 25():16-29. PubMed ID: 23909498
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the Mammalian Target of Rapamycin May Augment the Increase in Soluble Klotho Levels in Renal Transplantation Recipients.
Mizusaki K; Hasuike Y; Kimura T; Nagasawa Y; Kuragano T; Yamada Y; Nojima M; Yamamoto S; Nakanishi T; Ishihara M
Blood Purif; 2019; 47 Suppl 2():12-18. PubMed ID: 30943481
[TBL] [Abstract][Full Text] [Related]
18. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
[TBL] [Abstract][Full Text] [Related]
19. mTOR Inhibition and Clinical Transplantation: Kidney.
Flechner SM
Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
[No Abstract] [Full Text] [Related]
20. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
Paoletti E
Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
